MCID: LPC002
MIFTS: 45

Lip Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases

Aliases & Classifications for Lip Cancer

MalaCards integrated aliases for Lip Cancer:

Name: Lip Cancer 12 15 17
Malignant Neoplasm of Lip 12 32
Lip Neoplasms 44 70
Malignant Neoplasm of Oral Aspect of Lip, Not Specified Whether Upper or Lower 12
Malignant Neoplasm of External Lip, Not Specified As Upper or Lower 12
Malignant Neoplasm of Labial Commissure of Lip 12
Malignant Neoplasm of Lower Lip, Buccal Aspect 12
Malignant Neoplasm of Lower Lip, Inner Aspect 12
Malignant Neoplasm of Vermilion Border of Lip 12
Malignant Neoplasm of Lower Lip, Oral Aspect 12
Malignant Neoplasm of Lip, Vermilion Border 12
Malignant Neoplasm of Other Sites of Lip 12
Malignant Neoplasm of Commissure of Lip 12
Malignant Neoplasm of Lip, Inner Aspect 12
Malignant Neoplasm of Lower Lip, Mucosa 12
Malignant Tumor of Lower Labial Mucosa 12
Malignant Tumour of Labial Commissure 12
Malignant Tumor of Commissure of Lip 12
Malignant Neoplasm of Lip, External 12
Malignant Tumor of Labial Mucosa 12
Malignant Tumor of the Lip 12
Malignant Tumour of Lip 12
Malignant Tumor of Lip 12
Cancer of Lip 70

Classifications:



External Ids:

Disease Ontology 12 DOID:8564
ICD9CM 34 140 140.6 140.8
MeSH 44 D008048
NCIt 50 C7485
UMLS 70 C0023761 C0153340 C0153346 more

Summaries for Lip Cancer

MalaCards based summary : Lip Cancer, also known as malignant neoplasm of lip, is related to oral cancer and actinic cheilitis. An important gene associated with Lip Cancer is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Endometrial cancer and Measles. The drugs Heparin and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and endothelial, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Lip Cancer

Diseases in the Lip Cancer family:

Lip Carcinoma in Situ

Diseases related to Lip Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 125)
# Related Disease Score Top Affiliating Genes
1 oral cancer 31.6 TP53 MDM2 CDKN1A
2 actinic cheilitis 30.3 TP53 MSH2 MDM2 CDKN1A
3 cheilitis 30.3 TP53 MSH2 MDM2 CDKN1A
4 angiosarcoma 29.9 TP53 PDPN MDM2
5 basal cell carcinoma 29.7 TP53 MSH2 MDM2 CDKN1A CD44
6 skin carcinoma 29.6 TP53 MSH2 MDM2 CDKN1A CD44 BRAF
7 skin melanoma 29.4 TP53 MDM2 CDKN1A BRAF
8 adenocarcinoma 29.2 TP53 MSH2 MDM2 CDKN1A BRAF
9 squamous cell carcinoma 29.1 TP53 PDPN CDKN1A CD44 BRAF
10 lower lip cancer 11.3
11 upper lip cancer 11.2
12 ring chromosome 7 10.3 TP53 MDM2
13 ring chromosome 10.3 TP53 MDM2
14 esophagus verrucous carcinoma 10.3 TP53 MDM2
15 penile benign neoplasm 10.3 TP53 PDPN
16 undifferentiated embryonal sarcoma of the liver 10.3 TP53 MDM2
17 embryonal sarcoma 10.3 TP53 MDM2
18 pediatric liposarcoma 10.3 TP53 MDM2
19 xanthogranulomatous cholecystitis 10.3 TP53 PDPN
20 periosteal osteogenic sarcoma 10.3 TP53 MDM2
21 conjunctival squamous cell carcinoma 10.3 TP53 PDPN
22 maxillary sinus adenocarcinoma 10.3 TP53 MDM2
23 supraglottis cancer 10.3 TP53 PDPN
24 peripheral osteosarcoma 10.3 TP53 MDM2
25 soft tissue sarcoma 10.3 TP53 MDM2
26 parameningeal embryonal rhabdomyosarcoma 10.3 TP53 MDM2
27 nevus of ota 10.3 TP53 BRAF
28 conventional fibrosarcoma 10.3 TP53 MDM2
29 adult astrocytic tumour 10.3 TP53 MDM2
30 cervical adenoma malignum 10.3 TP53 MSH2
31 cervical adenosarcoma 10.3 TP53 MSH2
32 keratocystic odontogenic tumor 10.3 TP53 PDPN
33 spitz nevus 10.3 TP53 BRAF
34 malignant spiradenoma 10.3 TP53 MDM2
35 laryngeal benign neoplasm 10.3 TP53 PDPN
36 familial retinoblastoma 10.2 TP53 MDM2
37 anal squamous cell carcinoma 10.2 TP53 MDM2
38 sapho syndrome 10.2 TP53 MDM2
39 human papillomavirus infectious disease 10.2 TP53 CDKN1A
40 colorectal cancer, hereditary nonpolyposis, type 5 10.2 MSH2 BRAF
41 sarcomatoid renal cell carcinoma 10.2 TP53 MDM2
42 female reproductive endometrioid cancer 10.2 TP53 MSH2
43 suppressor of tumorigenicity 3 10.2 TP53 CDKN1A
44 bladder transitional cell papilloma 10.2 TP53 CDKN1A
45 adenofibroma 10.2 TP53 BRAF
46 melanotic neuroectodermal tumor 10.2 MDM2 BRAF
47 duodenum cancer 10.2 TP53 MSH2
48 invasive bladder transitional cell carcinoma 10.2 TP53 CDKN1A
49 duodenum disease 10.2 TP53 MSH2
50 nodular malignant melanoma 10.2 TP53 BRAF

Graphical network of the top 20 diseases related to Lip Cancer:



Diseases related to Lip Cancer

Symptoms & Phenotypes for Lip Cancer

GenomeRNAi Phenotypes related to Lip Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.28 CDKN1A
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.28 BRAF CDKN1A TP53
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.28 CDKN1A MDM2 MSH2 SUMO1 TP53

MGI Mouse Phenotypes related to Lip Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.86 BRAF CD44 CDKN1A MDM2 MSH2 PDPN
2 integument MP:0010771 9.7 BRAF CD44 CDKN1A MDM2 MSH2 PDPN
3 muscle MP:0005369 9.43 BRAF CD44 CDKN1A MDM2 PDPN TP53
4 neoplasm MP:0002006 9.1 BRAF CD44 CDKN1A MDM2 MSH2 TP53

Drugs & Therapeutics for Lip Cancer

Drugs for Lip Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 48)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Heparin Approved, Investigational Phase 3 9005-49-6 772 9812414
2
Cisplatin Approved Phase 2, Phase 3 15663-27-1 84093 441203 2767
3
Durvalumab Approved, Investigational Phase 2, Phase 3 1428935-60-7
4
Cetuximab Approved Phase 2, Phase 3 205923-56-4 56842117 2333
5 Hemostatics Phase 3
6 Coagulants Phase 3
7 Tolonium Chloride Phase 3
8 calcium heparin Phase 3
9
Erlotinib Hydrochloride Phase 3 183319-69-9 176871
10 Immunologic Factors Phase 2, Phase 3
11 Antibodies Phase 2, Phase 3
12 Immunoglobulins Phase 2, Phase 3
13 Immunoglobulin G Phase 2, Phase 3
14 Immunoglobulins, Intravenous Phase 2, Phase 3
15 Antibodies, Monoclonal Phase 2, Phase 3
16
Aminolevulinic acid Approved Phase 1, Phase 2 106-60-5 137
17 Orange Approved Phase 1, Phase 2
18
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
19
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
20 Photosensitizing Agents Phase 1, Phase 2
21 Dermatologic Agents Phase 1, Phase 2
22 Mitogens Phase 1, Phase 2
23 Tubulin Modulators Phase 2
24 Antimitotic Agents Phase 2
25 Albumin-Bound Paclitaxel Phase 2
26 Anti-Infective Agents Phase 2
27 Antidotes Phase 2
28 Chelating Agents Phase 2
29 Antioxidants Phase 2
30 Protective Agents Phase 2
31 sodium thiosulfate Phase 2
32 Antitubercular Agents Phase 2
33 Anti-Bacterial Agents Phase 2
34 Vaccines Phase 2
35
Gemcitabine Approved Phase 1 95058-81-4 60750
36
Doxycycline Approved, Investigational, Vet_approved Phase 1 564-25-0 54671203
37
Pembrolizumab Approved Phase 1 1374853-91-4
38 Pharmaceutical Solutions Phase 1
39 Antiviral Agents Phase 1
40 Antiparasitic Agents Phase 1
41 Antimalarials Phase 1
42 Antiprotozoal Agents Phase 1
43 Antineoplastic Agents, Immunological Phase 1
44
Nicotine Approved 54-11-5 942 89594
45
Ethanol Approved 64-17-5 702
46 Endothelial Growth Factors
47 Anesthetics
48 Tea

Interventional clinical trials:

(show all 48)
# Name Status NCT ID Phase Drugs
1 The Optimal Neck Treatments Strategy of Early Oral Cancer Based on Adverse Pathological Factor Recruiting NCT03017053 Phase 4
2 Canadian Optically Guided Approach for Oral Lesions Surgical Trial - COOLS Unknown status NCT01039298 Phase 3
3 Comparing the Test Characteristics of Three Oral Cancer Screening Techniques:1)Unaided Visual Examination 2)VelScope Examination and 3)Toluidine Blue Application, by Trained Primary Health Care Workers in Mumbai, India. Unknown status NCT00655421 Phase 3
4 Erlotinib Prevention of Oral Cancer (EPOC) Completed NCT00402779 Phase 3 Erlotinib;Placebo
5 Workplace Tobacco Cessation And Oral Cancer Screening Study Completed NCT00750503 Phase 3
6 Enhancing Self Care Among Oral Cancer Survivors: The Empowered Survivor Trial Recruiting NCT04713449 Phase 3
7 Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin Recruiting NCT03258554 Phase 2, Phase 3
8 Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer Recruiting NCT04333537 Phase 2, Phase 3 Imaging Agent
9 Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx Via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135] Completed NCT00064103 Phase 1, Phase 2
10 Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Completed NCT03638622 Phase 1, Phase 2
11 Bayesian Phase II Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer Recruiting NCT03224000 Phase 2
12 Multimodality Therapy With Induction Carboplatin/Nab-Paclitaxel/Durvalumab Followed by Surgical Resection and Risk-adapted Adjuvant Therapy for the Treatment of Locally-Advanced and Surgically Resectable Squamous Cell Carcinoma of the Head and Neck Recruiting NCT03174275 Phase 2 Durvalumab;Carboplatin;Nab-paclitaxel;Cisplatin
13 Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing Recruiting NCT02734537 Phase 2 Cisplatin
14 A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies Recruiting NCT03602079 Phase 1, Phase 2 A166
15 A Phase II Study of Sodium Thiosulfate (STS) for Prevention of Ototoxicity in Patients With Locally Advanced Squamous Cell Carcinoma of Head and Neck (SCCHN) Undergoing Concurrent Chemoradiation With Cisplatin Recruiting NCT04541355 Phase 2 Cisplatin;Sodium Thiosulfate
16 Phase II Trial of Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer Active, not recruiting NCT03258008 Phase 2 Utomilumab
17 Guided by Light: Optimizing Surgical Excision of Oral Cancer Using Real-time Fluorescence Imaging Not yet recruiting NCT04191460 Phase 2 cRGD-ZW800-1.
18 Phase I Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases Recruiting NCT03093909 Phase 1 Gemcitabine
19 Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) Recruiting NCT04533750 Phase 1 Peposertib
20 A Phase Ib Investigation of Pembrolizumab in Combination With Intratumoral Injection of Clostridium Novyi-NT in Patients With Treatment-Refractory Solid Tumors Recruiting NCT03435952 Phase 1 Pembrolizumab;Doxycycline
21 Phase I Trial of BAY1895344 ATR Inhibitor Combined With Stereotactic Body Radiation Therapy and Pembrolizumab for Recurrent Head and Neck Squamous Cell Carcinoma Not yet recruiting NCT04576091 Phase 1 Elimusertib
22 A Phase I Study of Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies Withdrawn NCT02812056 Phase 1 Alisertib;TAK-228
23 Phase I Study of Intraarterial ONYX-015 in Combination With Intravenous Cisplatin and Fluorouracil in Patients With Advanced Squamous Cell Cancer of the Head and Neck Withdrawn NCT00006106 Phase 1 cisplatin;fluorouracil;ONYX-015
24 A Phase I Trial of Lenvatinib (Multi-kinase Inhibitor) and Capecitabine (Anti-metabolite) in Patients With Advanced Malignancies Withdrawn NCT02915172 Phase 1 Lenvatinib;Capecitabine
25 The Role of Vascular Endothelial Growth Factor-C (VEGF-C) and Its Receptors Induced Lymphangiogenesis on the Carcinogenesis of Oral Cancers and Premalignant Lesions Unknown status NCT00173316
26 Oral State of Patients Affected by an Oral Cancer Before and After Radiotherapy - 3-years Prospective Study Unknown status NCT02866500
27 Dual-time PET/CT and Sentinel Node Diagnostics Preoperatively in Patients With Oral Cancer Unknown status NCT01136265
28 Observational Study on the Carcinogenesis of Gα12 in Oral Cancer, and Chemopreventive Possibility for the Treatment of Oral Cancer Using Ga12 Inhibitor. Unknown status NCT01919580
29 Observational Study on the Carcinogenesis of SOX-9 in Oral Cancer, and Chemopreventive Possibility for the Treatment of Oral Cancer Using SOX-9 Inhibitor. Unknown status NCT01919567
30 Validation of DNA Methylation Biomarkers for Oral Cancer Detection-Follow up Study Unknown status NCT02902406
31 A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations Completed NCT00186433
32 Epstein-Barr Detection in Squamous Cell Carcinoma and Healthy Oral Mucosa Completed NCT01039272
33 Rehabilitation Outcomes of Shoulder Function in Oral Cancer Survivors Cancer Survivors Completed NCT03545100
34 Behavior Change on Oral Cancer Patients After a Localized Behavior Change Model Intervention Completed NCT01351532
35 Effectiveness of Green Tea Mouthwash on the Oral Health Status in Oral Cancer Patients: A Single-blind Randomized Clinical Trial and a CONSORT-compliant Article Completed NCT04615780
36 Using an APP in Post Oral Cancer Surgery to Affect Patients' Needs and Quality of Life. Completed NCT04049968
37 Validation of DNA Methylation Biomarkers for Oral Cancer Detection Completed NCT01945697
38 Web-based Education on Oral Cancer for Primary Care Physicians in Ohio Completed NCT01424358
39 Validation of DNA Methylation Biomarkers for Oral Cancer Detection Completed NCT02648789
40 Randomized Intervention Trial to Evaluate Oral Visual Inspection in the Control of Oral Cancer Completed NCT04494620
41 Retrospective Analysis Of Sensory Recovery Of Donor Size And Related Quality Life In Oral Cancer Patients Receiving Free Flap Reconstruction Completed NCT02048631
42 Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers Recruiting NCT00568490
43 Yeur-Hur Lai, PhD, RN, School of Nursing, College of Medicine, National Taiwan University Recruiting NCT04214912
44 Integrated Cancer Repository for Cancer Research Recruiting NCT02012699
45 Dyadic Yoga Intervention for Patient With Head and Neck Cancer Undergoing Radiotherapy and Their Family Caregivers Active, not recruiting NCT03114501
46 Correlative Study of Nicotine Levels With Response Rates to Therapy Using Radiation Alone or in Combination With Chemotherapy in Head and Neck Cancer Active, not recruiting NCT01084733
47 Clinical Evaluation of the OncAlert RAPID; Impact on Decision-Making Active, not recruiting NCT03239834
48 THE HONG KONG ORAL CANCER EDUCATION AND SCREENING (HOCES) PROGRAM: REFINING DISEASE PREVENTION, RISK STRATIFICATION AND EARLY DETECTION Not yet recruiting NCT04487938

Search NIH Clinical Center for Lip Cancer

Cochrane evidence based reviews: lip neoplasms

Genetic Tests for Lip Cancer

Anatomical Context for Lip Cancer

MalaCards organs/tissues related to Lip Cancer:

40
Skin, Lymph Node, Endothelial, Tongue, Thyroid, Salivary Gland, Neutrophil

Publications for Lip Cancer

Articles related to Lip Cancer:

(show top 50) (show all 471)
# Title Authors PMID Year
1
A short review on DNA damage and repair effects in lip cancer. 61
33626329 2021
2
The relevance of miRNAs as promising biomarkers in lip cancer. 61
33439343 2021
3
Trends in mortality rates for oral and oropharyngeal cancer in Spain, 1979-2018. 61
33305413 2020
4
Application of vermillion myocutaneous flap in restoration after lip cancer resection. 61
32951304 2020
5
State Medicaid expansion status, insurance coverage and stage at diagnosis in head and neck cancer patients. 61
32629408 2020
6
Risk of squamous cell carcinoma of the lip and cutaneous melanoma in older Australians using hydrochlorothiazide: A population-based case-control study. 61
32608576 2020
7
Immunohistochemical analysis of epithelium adjacent to lip cancer: A meta-analysis. 61
32945581 2020
8
Predictive factors of late neck metastasis in early stage lip cancer followed by "wait and see" policy. 61
32526529 2020
9
Cancer incidence among seafarers and fishermen in the Nordic countries. 61
31917456 2020
10
Lower Lip Cancer Managed by Reconstruction with a Double Abbe Flap - A Case Report. 61
33708599 2020
11
Association between hydrochlorothiazide exposure and different incident skin, lip and oral cavity cancers: A series of population-based nested case-control studies. 61
32068906 2020
12
The Upper Lip Squamous Cell Carcinoma the Role of Wedge Excision. 61
32068722 2020
13
Fusuma Sliding Flap for Lip Reconstruction of Lower Lip Cancer. 61
32209936 2020
14
Predictors of occult lymph node metastases in lip cancer. 61
32081379 2020
15
High dose rate interstitial brachytherapy for early stage lip cancer using customized dental spacer. 61
32266411 2020
16
Analysis of the Filipinos' Interest in Searching Online for Oral Cancer. 61
32334480 2020
17
Erratum: Facial cutaneous metastases of advanced rectal malignancy masquerading as lip cancer. 61
32270784 2020
18
Pointless spatial modeling. 61
30202860 2020
19
A Novel Method for Reconstruction of the Lower Lip After Lip Cancer Ablation: Double Abbe Flap. 61
31785249 2020
20
Global patterns and trends in cancers of the lip, tongue and mouth. 61
31986342 2020
21
Detection of Occult Metastases in Patients with T1 and T2 Stage Lower Lip Squamous Cell Carcinomas after Positive Lymphoscintigraphy. 61
32053939 2020
22
Case report of a huge lower lip cancer successfully treated with intra-arterial infusion chemotherapy. 61
32446228 2020
23
Can immunohistochemical biomarkers distinguish epithelial dysplasia degrees in actinic cheilitis? A systematic review and meta-analysis. 61
31880283 2020
24
Use of hydrochlorothiazide and risk of skin cancer: a nationwide Taiwanese case-control study. 61
31673105 2019
25
Predictive factors for late cervical metastasis in stage I and II squamous cell carcinoma of the lip. 61
31161362 2019
26
A bibliometric analysis of the most cited articles about squamous cell carcinoma of the mouth, lips, and oropharynx. 61
31076327 2019
27
Cancer incidence and mortality after heart transplantation - A population-based national cohort study. 61
30821595 2019
28
The stem cell markers expression CD44v6 and podoplanin in lip cancer: clinical significance. 61
30770986 2019
29
Preoperative neutrophil lymphocyte ratio but not platelet lymphocyte ratio predicts survival and early relapse in patients with oral, pharyngeal, and lip cancer. 61
30633409 2019
30
Impact of varying anatomic sites on advanced stage and survival of oral cancer: 9-year prospective cohort of 27 717 cases. 61
30652378 2019
31
Lip cancer: Reconsidering the at-risk patients with pathological assessment. 61
30548899 2019
32
Cancer incidence in the Agricultural Health Study after 20 years of follow-up. 61
30805813 2019
33
Plasma cell cheilitis: the diagnosis of a disorder mimicking lip cancer. 61
30963053 2019
34
Adjuvant interstitial three-dimensional pulse-dose-rate-brachytherapy for lip squamous cell carcinoma after surgical resection. 61
31139219 2019
35
A Comparison of the NCDB and SEER Database for Research Involving Head and Neck Cancer. 61
30129822 2019
36
Risk of lip cancer after solid organ transplantation in the United States. 61
30074684 2019
37
Total lower lip reconstruction by bilateral Fujimori technique-A case report. 61
31035229 2019
38
Squamous Cell Carcinoma of Lower Lip Reconstructed with Bilateral Fan Flap. 61
31293957 2019
39
Photosensitizing antihypertensive drug use and risk of cutaneous squamous cell carcinoma. 61
29723931 2018
40
Malignant transformation of actinic cheilitis: A systematic review of observational studies. 61
29863311 2018
41
Incidence of first and second primary cancers diagnosed among people with HIV, 1985-2013: a population-based, registry linkage study. 61
30245004 2018
42
DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF 59 PATIENTS WITH LIP CANCER AT A TERTIARY UNIVERSITY HOSPITAL IN TURKEY - A SINGLE-CENTER EXPERIENCE. 61
30618385 2018
43
Antihypertensive drugs and risk of skin cancer. 61
29368863 2018
44
Lip reconstruction technique: A modified Abbe-Estlander with a myomucosal advancement flap. 61
29183823 2018
45
Immunoexpression of glucocorticoid receptor alpha (GRα) isoform and apoptotic proteins (Bcl-2 and Bax) in actinic cheilitis and lower lip squamous cell carcinoma. 61
29935090 2018
46
Cancer incidence among merchant seafarers: an extended follow-up of a Danish cohort. 61
29779004 2018
47
Expression of cancer stem cell markers CD44, ALDH1 and p75NTR in actinic cheilitis and lip cancer. 61
29779037 2018
48
The association between immunoexpression levels of oxidant and antioxidant enzymes and lip squamous cell carcinoma. 61
29630749 2018
49
Moesin Involvement in Oral Carcinogenesis of the Lower Lip. 61
29715096 2018
50
[Incidence of type 2 diabetes among oral cancer patients in Hungary]. 61
29754510 2018

Variations for Lip Cancer

Expression for Lip Cancer

Search GEO for disease gene expression data for Lip Cancer.

Pathways for Lip Cancer

Pathways related to Lip Cancer according to GeneCards Suite gene sharing:

(show all 39)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.71 TP53 MSH2 MDM2 CDKN1A BRAF
2
Show member pathways
12.68 TP53 MDM2 CDKN1A CD44
3 12.68 TP53 MSH2 MDM2 CDKN1A BRAF
4
Show member pathways
12.55 TP53 MDM2 CDKN1A BRAF
5
Show member pathways
12.52 TP53 SUMO1 MDM2 CDKN1A
6
Show member pathways
12.51 TP53 SUMO1 MSH2 MDM2 CDKN1A
7
Show member pathways
12.49 TP53 MDM2 CDKN1A BRAF
8 12.4 TP53 MDM2 CDKN1A CD44
9 12.36 TP53 MSH2 MDM2 CDKN1A
10 12.14 TP53 MDM2 CDKN1A
11
Show member pathways
12.12 TP53 MDM2 CDKN1A
12
Show member pathways
12.11 TP53 MDM2 CDKN1A BRAF
13 12.03 TP53 MDM2 CDKN1A
14 12 TP53 MSH2 CDKN1A BRAF
15
Show member pathways
11.97 MDM2 CDKN1A BRAF
16 11.97 TP53 MDM2 CDKN1A CD44 BRAF
17 11.95 TP53 SUMO1 CDKN1A
18 11.95 TP53 MSH2 MDM2 BRAF
19 11.88 TP53 MDM2 CDKN1A
20 11.85 TP53 MSH2 MDM2 CDKN1A
21 11.75 SUMO1 MDM2 CDKN1A
22 11.75 TP53 MDM2 CDKN1A BRAF
23 11.73 TP53 MDM2 CDKN1A
24
Show member pathways
11.71 TP53 MDM2 CDKN1A
25 11.67 TP53 MDM2 CDKN1A
26 11.53 TP53 SUMO1 MDM2 CDKN1A
27 11.53 TP53 MSH2 MDM2 CDKN1A
28 11.49 TP53 MDM2 CDKN1A BRAF
29
Show member pathways
11.46 TP53 SUMO1 MDM2
30 11.42 TP53 CDKN1A CD44
31 11.38 TP53 MDM2 CDKN1A CD44 BRAF
32 11.34 TP53 MDM2 CDKN1A
33 11.17 TP53 MDM2
34 11.12 TP53 MSH2 MDM2 CDKN1A
35 11.01 TP53 MDM2
36 10.71 TP53 CDKN1A
37 10.67 SUMO1 MDM2
38
Show member pathways
10.48 TP53 CDKN1A
39
Show member pathways
10.27 TP53 SUMO1 MDM2 CDKN1A

GO Terms for Lip Cancer

Cellular components related to Lip Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lamellipodium membrane GO:0031258 8.96 PDPN CD44
2 nuclear body GO:0016604 8.92 TP53 SUMO1 MDM2 CDKN1A

Biological processes related to Lip Cancer according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 protein stabilization GO:0050821 9.77 TP53 SUMO1 CDKN1A
2 cell cycle arrest GO:0007050 9.75 TP53 MSH2 CDKN1A
3 positive regulation of proteasomal ubiquitin-dependent protein catabolic process GO:0032436 9.65 ZER1 SUMO1 MDM2
4 positive regulation of reactive oxygen species metabolic process GO:2000379 9.61 TP53 CDKN1A
5 intrinsic apoptotic signaling pathway GO:0097193 9.61 TP53 CDKN1A
6 positive regulation of protein export from nucleus GO:0046827 9.59 TP53 MDM2
7 determination of adult lifespan GO:0008340 9.58 TP53 MSH2
8 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.58 TP53 MDM2 CDKN1A
9 mitotic cell cycle arrest GO:0071850 9.57 TP53 CDKN1A
10 replicative senescence GO:0090399 9.56 TP53 CDKN1A
11 wound healing, spreading of cells GO:0044319 9.55 PDPN CD44
12 response to hyperoxia GO:0055093 9.54 PDPN CDKN1A
13 negative regulation of DNA damage response, signal transduction by p53 class mediator GO:0043518 9.52 MDM2 CD44
14 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.51 TP53 CDKN1A
15 cardiac septum morphogenesis GO:0060411 9.49 TP53 MDM2
16 cellular response to UV-C GO:0071494 9.46 TP53 MDM2
17 signal transduction by p53 class mediator GO:0072331 9.43 TP53 CDKN1A
18 cellular response to gamma radiation GO:0071480 9.43 TP53 MDM2 CDKN1A
19 regulation of lamellipodium morphogenesis GO:2000392 9.37 PDPN CD44
20 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.33 TP53 MSH2 CDKN1A
21 cellular response to actinomycin D GO:0072717 9.32 TP53 MDM2
22 response to X-ray GO:0010165 9.13 TP53 MSH2 CDKN1A
23 negative regulation of apoptotic process GO:0043066 9.1 TP53 PDPN MDM2 CDKN1A CD44 BRAF

Molecular functions related to Lip Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.26 TP53 SUMO1 MSH2 MDM2
2 ubiquitin protein ligase binding GO:0031625 8.92 TP53 SUMO1 MDM2 CDKN1A

Sources for Lip Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....